Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cell biology
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • Older

Cell Biology Articles & Analysis: Older

72 news found

Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Customer Success Story: Why Clean Cells Chose VIPS PRO: The Need for Clonality & GMP Compatibility

Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...

ByAdvanced Instruments


Creative Biostructure Launches Structured Illumination Microscopy Service for Enhanced Imaging Capabilities

Creative Biostructure Launches Structured Illumination Microscopy Service for Enhanced Imaging Capabilities

The SIM service offered by Creative Biostructure includes Ultra-high resolution Fluorescence microscopy imaging service for tubulin in living cells (Green Fluorescence)/ lysosomes in living cells (Deep Red Fluorescence/Orange Fluorescence)/ mitochondria in living cells (Deep Red Fluorescence)/ nuclei in living cells (Deep Red ...

ByCreative Biostructure


CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material

CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material

CELLINK and Ossiform will be at the American Society of Cell biology conference, taking place in Boston from December 2nd to 6th, to present Ossi Ink and demonstrate the versatility that this material will provide researchers. ...

ByCELLINK


Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

More and more studies have shown that R-phycoerythrin (R-PE) labeled proteins have broad application prospects in laboratory applications, biopharmaceutical and diagnostic technologies, as well as biological imaging. For cell and molecular biology research, R-PE labeled protein can be used as a biomarker in cellular immune analysis, and can also be used as a ...

ByCreative BioMart


FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

It is crucial for the identification of novel biomarkers, the diagnosis of diseases such as Alzheimer's, and the biological analysis of drug development processes.POWCLIN, a subsidiary of FPI's Life Sciences division, has developed its own cell analysis-focused SFLO series of full-spectrum flow cytometers and MSFLO benchtop mass spectrometry flow cytometers. The SFLO series is ...

ByFocused Photonics Inc. (FPI)


CD Formulation: Pharmaceutical Analysis Brings More Confidence to Drug Development and GMP Manufacturing

CD Formulation: Pharmaceutical Analysis Brings More Confidence to Drug Development and GMP Manufacturing

Analysis and Testing Services Taking advantage of its extensive technical expertise in biochemistry, molecular and cell biology, chemistry, and microbiology, CD Formulation can provide comprehensive, innovative, and timely solutions to help customers quickly complete their drug analysis testing requirements. ...

ByCD Formulation


Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin Announces Expansion of Laboratory Testing Capability

Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and other prominent leaders in the relevant fields of study. ...

ByLifespin GmbH


Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Alfa Chemistry Newly Releases Phospholipids, Modified Lipids, and Functionalized Lipids

Lipids are essential to many body functions and serve as the building blocks for living cells. Alfa Chemistry has been an ISO 9001:2015 certified supplier of nearly all forms of lipids and fatty acids and continues to broaden its product lines by adding phospholipids, modified lipids, and functionalized lipids. ...

ByAlfa Chemistry


Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies

Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies

Mariola Fotin-Mleczek, PhD, is an internationally recognized specialist in the field of immunology and cell biology. For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. ...

ByArdigen


Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron

We hope to establish our pipeline products as the preferred combination agents with T cell checkpoint inhibitors and other standard of care therapies.” The Phase 1 expansion phase includes IO-108 monotherapy cohorts and IO-108 combination cohorts with anti-PD-1 antibodies (pembrolizumab or cemiplimab, depending on tumor types). ...

ByImmune-Onc Therapeutics, Inc.


Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update

Immune-Onc Therapeutics Announces Appointment of Christopher Whitmore as Chief Financial Officer and Provides Clinical Progress Update

“We look forward to advancing IO-108 into multiple expansion cohorts in specific tumor types as monotherapy and in combination with T cell checkpoint inhibitors.” ABOUT IO-108 IO-108 is a fully human IgG4 monoclonal antibody with high affinity and specificity towards LILRB2 (also known as ILT4). ...

ByImmune-Onc Therapeutics, Inc.


Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China

Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China

In hematologic malignancies, preclinical studies showed that IO-202 converts a “don’t kill me” to a “kill me” signal by activating T cell killing and converts a “don’t find me” to a “find me” signal by inhibiting infiltration of blood cancer cells. In the context of solid tumors, preclinical data ...

ByImmune-Onc Therapeutics, Inc.


Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services

Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services

“The comprehensive and quantitative metabolic profiling services will enable pharmaceutical companies in particular to perform a range of precision phenotyping of cell or animal models and patient cohorts. Leveraging Lifespin’s Comprehensive Metabolic Database Lifespin has built one of the largest and most comprehensive databases of metabolic health profiles across ...

ByLifespin GmbH


Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-108 in Patients with Advanced Solid Tumors in China

Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-108 in Patients with Advanced Solid Tumors in China

This data enables the company to accelerate the global development of IO-108 in multiple expansion cohorts in select cancers as a monotherapy and in combination with T cell checkpoint inhibitors. The IO-108 Phase 1 clinical trial in China (NCT05508100) is currently enrolling patients. ...

ByImmune-Onc Therapeutics, Inc.


Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development

Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development

Rizo served in a number of oncology drug development functions with increasing responsibilities at Janssen Research and Development, LLC (Janssen), including Senior Director, Compound Development Team Leader for all myeloid assets, Senior Director, Global Clinical Leader for the imetelstat, ibrutinib mantle cell lymphoma (MCL) program, and others. In these roles, she had ...

ByBayer AG


Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project

Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project

Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of proteins. Therefore, the study of protein ubiquitination plays an important role in cell biology and drug discovery. With the comprehensive ...

ByProfacgen


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

ABOUT LILRB2 (ILT4) LILRB2, also known as ILT4, is expressed mostly by myeloid cells, including monocytes, macrophages, dendritic cells, and neutrophils. ...

ByImmune-Onc Therapeutics, Inc.


Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo

Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo

(Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18th Annual PEGS Boston Conference, a protein engineering and cell therapy summit, being held virtually and in person from May 2-6, 2022 at the Hynes Convention Center. ...

ByBruker Corporation


Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

The data being presented suggest that LAIR1 antagonist antibodies reverse collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, thereby promoting anti-tumor immunity. ...

ByImmune-Onc Therapeutics, Inc.


Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

This research has rapidly advanced a completely new field of study and class of cancer immunotherapy that goes beyond T cells to overcome immune resistance and the limitations of current treatment options. ...

ByImmune-Onc Therapeutics, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT